• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Says Hold Onto This Tech Stock, But 'You're Not Going To Make A Lot Of Money In It Right Now, Because That Was A Really Terrible Last Quarter'

    10/31/23 9:12:17 AM ET
    $GLW
    $MRK
    $TXN
    $VRTV
    Telecommunications Equipment
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLW alert in real time by email

    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Corning Incorporated (NYSE:GLW) reported a disappointing quarter. "In this market, it stays disappointing, there’s just no bounce, maybe next year," he noted.

    Cramer said Vertiv Holdings Co (NYSE:VRTV) is a Buy.

    Don’t forget to check out our premarket coverage here

    The "Mad Money" host recommended holding Texas Instruments Incorporated (NASDAQ:TXN). "Now, they are very shareholder friendly, but then again, they do have a lot of industrial that is not doing that well… [but] you’re not going to make a lot of money in it right now, because that was a really terrible last quarter," he added.

    Merck & Co., Inc. (NYSE:MRK) is doing "very, very well," he said.

    Price Action: Shares of Merck fell 0.1% to close at $102.68, while Texas Instruments fell 0.9% to $140.50 on Monday. Vertiv rose 5.1% to settle at $38.28, while Corning gained 0.3% to close at $26.66 during Monday’s session

    Now Read This: Investor Fear Eases Ahead Of Fed's Decision; Dow Notches Best Day Since June

    Photo: Shutterstock

    Get the next $GLW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLW
    $MRK
    $TXN
    $VRTV

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Corning Incorporated
    $GLW
    1/29/2026Overweight → Equal Weight
    Fox Advisors
    Texas Instruments Incorporated
    $TXN
    1/28/2026$235.00Underperform → Neutral
    BofA Securities
    Texas Instruments Incorporated
    $TXN
    1/28/2026$225.00 → $240.00Buy
    TD Cowen
    Texas Instruments Incorporated
    $TXN
    1/22/2026$190.00Underperform → Neutral
    BNP Paribas Exane
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $GLW
    $MRK
    $TXN
    $VRTV
    SEC Filings

    View All

    SEC Form 13F-HR filed by Merck & Company Inc.

    13F-HR - Merck & Co., Inc. (0000310158) (Filer)

    2/17/26 4:01:41 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Corning Incorporated

    10-K - CORNING INC /NY (0000024741) (Filer)

    2/12/26 4:41:48 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    SEC Form 10-K filed by Texas Instruments Incorporated

    10-K - TEXAS INSTRUMENTS INC (0000097476) (Filer)

    2/6/26 11:06:56 AM ET
    $TXN
    Semiconductors
    Technology

    $GLW
    $MRK
    $TXN
    $VRTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. Vice President Kozanian Hagop H sold $1,546,168 worth of shares (6,843 units at $225.95), decreasing direct ownership by 8% to 75,425 units (SEC Form 4)

    4 - TEXAS INSTRUMENTS INC (0000097476) (Issuer)

    2/18/26 4:58:50 PM ET
    $TXN
    Semiconductors
    Technology

    Senior Vice President & CHRO Gullo Michelle L sold $5,977 worth of Common Stock - Held by Spouse (44 units at $135.83) and sold $76,962 worth of shares (587 units at $131.11), decreasing direct ownership by 2% to 36,000 units (SEC Form 4)

    4 - CORNING INC /NY (0000024741) (Issuer)

    2/13/26 4:00:16 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    Exec. Vice President & CCDO Zhang John Z sold $204,765 worth of shares (1,531 units at $133.75), closing all direct ownership in the company (SEC Form 4)

    4 - CORNING INC /NY (0000024741) (Issuer)

    2/12/26 5:02:52 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    $GLW
    $MRK
    $TXN
    $VRTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLW
    $MRK
    $TXN
    $VRTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

    Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authorities Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease over two RSV seasons. The data were presented during an oral session (Abstract #P455) at RSVVW'26, the 9th conference of the Respiratory Syncytial Virus Foundation (ReSViNET) i

    2/19/26 5:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

    Strategic collaboration brings together Mayo Clinic's extensive clinical insights, genomic data and Platform architecture with Merck's artificial intelligence (AI) and machine learning (ML) research capabilities Merck (NYSE:MRK), known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic's Platform architecture as well as clinical and genomic datasets with Merck's ambition to harness AI-enabled virtual cell technologies to enhance

    2/18/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLW
    $MRK
    $TXN
    $VRTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corning downgraded by Fox Advisors

    Fox Advisors downgraded Corning from Overweight to Equal Weight

    1/29/26 7:56:33 AM ET
    $GLW
    Telecommunications Equipment
    Industrials

    $GLW
    $MRK
    $TXN
    $VRTV
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Treasury Guidance Supports T1's Tax Credit Eligibility

    AUSTIN, Texas and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE:TE) ("T1," "T1 Energy," or the "Company") supports policy that favors the revival of advanced American manufacturing and energy dominance in accordance with the One Big Beautiful Bill Act ("OBBBA"). The initial guidance provided by the U.S. Department of Treasury last week on the implementation of the OBBBA foreign entity of concern ("FEOC") provisions is consistent with T1's expectations and supports T1's analysis of its eligibility for Section 45X tax credits. "T1 is an American-owned and controlled company committed to investing in advanced American manufacturing, building a domestic and non-FEOC solar s

    2/17/26 6:10:23 AM ET
    $GLW
    $NXT
    $TE
    Telecommunications Equipment
    Industrials
    Industrial Machinery/Components
    Miscellaneous

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $GLW
    $MRK
    $TXN
    $VRTV
    Financials

    Live finance-specific insights

    View All

    Corning Announces Quarterly Dividend

    Corning Incorporated's (NYSE:GLW) Board of Directors today declared a quarterly dividend of $0.28 per share. The dividend will be payable on March 30, 2026, to shareholders of record on February 27, 2026. Caution Concerning Forward-Looking Statements The statements contained in this release and related comments by management that are not historical facts or information and contain words such as "will," "believe," "anticipate," "expect," "intend," "plan," "seek," "see," "would," "target," "estimate," "forecast" or similar expressions are forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform

    2/11/26 2:49:00 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    Texas Instruments to acquire Silicon Labs

    Enhances global leadership in embedded wireless connectivity solutions Leverages Texas Instruments' industry-leading, dependable, low-cost manufacturing capacity to better serve customers Deepens customer engagement through Texas Instruments' reach of market channels and cross-sell opportunities Expected to generate ~$450 million of annual manufacturing and operational synergies within three years post-close DALLAS and AUSTIN, Texas, Feb. 4, 2026 /PRNewswire/ -- Texas Instruments (NASDAQ:TXN), a global semiconductor company that designs, manufactures and sells analog and embedded processing chips, and Silicon Labs (NASDAQ:SLAB), a leader in secure, intelligent wireless technology, today ann

    2/4/26 7:00:00 AM ET
    $SLAB
    $TXN
    Semiconductors
    Technology

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLW
    $MRK
    $TXN
    $VRTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corning Incorporated

    SC 13G/A - CORNING INC /NY (0000024741) (Subject)

    11/22/24 6:06:27 AM ET
    $GLW
    Telecommunications Equipment
    Industrials

    Amendment: SEC Form SC 13G/A filed by Corning Incorporated

    SC 13G/A - CORNING INC /NY (0000024741) (Subject)

    8/12/24 6:01:50 AM ET
    $GLW
    Telecommunications Equipment
    Industrials

    SEC Form SC 13G/A filed by Texas Instruments Incorporated (Amendment)

    SC 13G/A - TEXAS INSTRUMENTS INC (0000097476) (Subject)

    6/10/24 12:15:17 PM ET
    $TXN
    Semiconductors
    Technology